{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T22:12:42Z","timestamp":1767996762220,"version":"3.49.0"},"reference-count":40,"publisher":"Impact Journals, LLC","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging"],"published-print":{"date-parts":[[2022,10,15]]},"DOI":"10.18632\/aging.204324","type":"journal-article","created":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T16:39:21Z","timestamp":1665247161000},"page":"7941-7958","source":"Crossref","is-referenced-by-count":6,"title":["ERAP2 as a potential biomarker for predicting gemcitabine response in patients with pancreatic cancer"],"prefix":"10.18632","volume":"14","author":[{"given":"Pian","family":"Yu","sequence":"first","affiliation":[{"name":"The Department of Dermatology, Xiangya Hospital, Central South University, Changsha 410000, Hunan, China"},{"name":"National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Xiangya Hospital, Changsha 410000, Hunan, China"},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha 410000, Hunan, China"},{"name":"Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Changsha 410000, Hunan, China"},{"name":"Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Changsha 410000, Hunan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shifu","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaxin","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[{"name":"The Department of Dermatology, Xiangya Hospital, Central South University, Changsha 410000, Hunan, China"},{"name":"National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Xiangya Hospital, Changsha 410000, Hunan, China"},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha 410000, Hunan, China"},{"name":"Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Changsha 410000, Hunan, China"},{"name":"Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Changsha 410000, Hunan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cong","family":"Peng","sequence":"additional","affiliation":[{"name":"The Department of Dermatology, Xiangya Hospital, Central South University, Changsha 410000, Hunan, China"},{"name":"National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Xiangya Hospital, Changsha 410000, Hunan, China"},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha 410000, Hunan, China"},{"name":"Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Changsha 410000, Hunan, China"},{"name":"Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Changsha 410000, Hunan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2022,10,8]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.ejso.2016.10.023","article-title":"Radical surgery of oligometastatic pancreatic cancer.","volume":"4","author":"B\u00fcchler","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"2","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic Cancer: A Review.","volume":"32","author":"O\u2019Reilly","year":"2021","journal-title":"JAMA"},{"key":"3","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","article-title":"Pancreatic cancer.","volume":"39","author":"Shroff","year":"2020","journal-title":"Lancet"},{"key":"4","doi-asserted-by":"publisher","first-page":"4504","DOI":"10.3390\/ijms20184504","article-title":"Chemoresistance in Pancreatic Cancer.","volume":"2","author":"Yang","year":"2019","journal-title":"Int J Mol Sci"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1002\/mas.21748","article-title":"The next \u201csweet\u201d spot for pancreatic ductal adenocarcinoma: Glycoprotein for early detection.","author":"Zhang","year":"2021","journal-title":"Mass Spectrom Rev"},{"key":"6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/s0093-7754(03)00296-3","article-title":"New perspectives in the management of pancreas cancer.","volume":"3","author":"Haller","year":"2003","journal-title":"Semin Oncol"},{"key":"7","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3109\/0284186X.2015.1096020","article-title":"Does long-term survival exist in pancreatic adenocarcinoma?","volume":"5","author":"Creemers","year":"2016","journal-title":"Acta Oncol"},{"key":"8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018.","volume":"6","author":"Jemal","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"9","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1080\/03602530902741828","article-title":"Clinical pharmacology and pharmacogenetics of gemcitabine.","volume":"4","author":"Innocenti","year":"2009","journal-title":"Drug Metab Rev"},{"key":"10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00280-016-3003-0","article-title":"Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective.","volume":"7","author":"Giovannetti","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"11","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/s41397-020-00203-7","article-title":"Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel.","volume":"2","author":"Del Re","year":"2021","journal-title":"Pharmacogenomics J"},{"key":"12","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.","volume":"1","author":"Von Hoff","year":"1997","journal-title":"J Clin Oncol"},{"key":"13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.drup.2015.10.002","article-title":"Gemcitabine resistance in pancreatic ductal adenocarcinoma.","volume":"2","author":"Gil","year":"2015","journal-title":"Drug Resist Updat"},{"key":"14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1615\/CritRevOncog.2019031641","article-title":"Gemcitabine: A Review of Chemoresistance in Pancreatic Cancer.","volume":"2","author":"Ahmad","year":"2019","journal-title":"Crit Rev Oncog"},{"key":"15","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3390\/cancers9110157","article-title":"Pancreatic Cancer Chemoresistance to Gemcitabine.","volume":"9","author":"Gladhaug","year":"2017","journal-title":"Cancers (Basel)"},{"key":"16","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ctrv.2008.10.002","article-title":"Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer.","volume":"3","author":"Raymond","year":"2009","journal-title":"Cancer Treat Rev"},{"key":"17","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ctrv.2017.05.001","article-title":"Critical focus on mechanisms of resistance and toxicity of m-TOR inhibitors in pancreatic neuroendocrine tumors.","volume":"5","author":"Fazio","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"18","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1136\/gutjnl-2012-303588","article-title":"Current concepts and novel targets in advanced pancreatic cancer.","volume":"6","author":"Gress","year":"2013","journal-title":"Gut"},{"key":"19","doi-asserted-by":"publisher","first-page":"D955","DOI":"10.1093\/nar\/gks1111","article-title":"Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells.","volume":"4","author":"Haber","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"20","doi-asserted-by":"crossref","unstructured":"The TCGA Legacy. Cell. 2018; 173:281-2. https:\/\/doi.org\/10.1016\/j.cell.2018.03.049.","DOI":"10.1016\/j.cell.2018.03.049"},{"key":"21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejphar.2014.07.041","article-title":"Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer.","volume":"74","author":"Monteiro","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"22","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.canlet.2018.08.010","article-title":"USP9X inhibition improves gemcitabine sensitivity in pancreatic cancer by inhibiting autophagy.","volume":"43","author":"Liang","year":"2018","journal-title":"Cancer Lett"},{"key":"23","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/jb\/mvt066","article-title":"Endoplasmic reticulum aminopeptidases: biochemistry, physiology and pathology.","volume":"15","author":"Tsujimoto","year":"2013","journal-title":"J Biochem"},{"key":"24","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/art.40369","article-title":"Genetic Variants in ERAP1 and ERAP2 Associated With Immune-Mediated Diseases Influence Protein Expression and the Isoform Profile.","volume":"7","author":"Brown","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"25","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1136\/annrheumdis-2015-207416","article-title":"ERAP2 is associated with ankylosing spondylitis in HLA-B27-positive and HLA-B27-negative patients.","volume":"7","author":"Garchon","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"26","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.humimm.2019.02.014","article-title":"Regulation of ERAP1 and ERAP2 genes and their disfunction in human cancer.","volume":"8","author":"Fruci","year":"2019","journal-title":"Hum Immunol"},{"key":"27","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/bjc.2015.297","article-title":"HLA class I is most tightly linked to levels of tapasin compared with other antigen-processing proteins in glioblastoma.","volume":"11","author":"Paulsson","year":"2015","journal-title":"Br J Cancer"},{"key":"28","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/biolre\/ioy001","article-title":"The role of endoplasmic reticulum aminopeptidase 2 in modulating immune detection of choriocarcinoma.","volume":"9","author":"Lee","year":"2018","journal-title":"Biol Reprod"},{"key":"29","doi-asserted-by":"publisher","first-page":"788985","DOI":"10.3389\/fimmu.2021.788985","article-title":"ERAP2 Is Associated With Immune Infiltration and Predicts Favorable Prognosis in SqCLC.","volume":"1","author":"Fan","year":"2021","journal-title":"Front Immunol"},{"key":"30","doi-asserted-by":"publisher","first-page":"61698","DOI":"10.18632\/oncotarget.18680","article-title":"Endoplasmic reticulum aminopeptidase 2 involvement in metastasis of oral cavity squamous cell carcinoma discovered by proteome profiling of primary cancer cells.","volume":"8","author":"Chang","year":"2017","journal-title":"Oncotarget"},{"key":"31","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1093\/jnci\/djt184","article-title":"MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells.","volume":"10","author":"Racanelli","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"32","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.placenta.2017.03.012","article-title":"Endoplasmic Reticulum Aminopeptidase 2, a common immunological link to adverse pregnancy outcomes and cancer clearance?","volume":"5","author":"Lee","year":"2017","journal-title":"Placenta"},{"key":"33","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.2174\/0929867325666180214111849","article-title":"Inhibitors of ER Aminopeptidase 1 and 2: From Design to Clinical Application.","volume":"2","author":"Stratikos","year":"2019","journal-title":"Curr Med Chem"},{"key":"34","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/nrg1879","article-title":"The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism.","volume":"7","author":"Cantley","year":"2006","journal-title":"Nat Rev Genet"},{"key":"35","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrclinonc.2018.28","article-title":"Targeting the PI3K pathway in cancer: are we making headway?","volume":"1","author":"Meric-Bernstam","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"36","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.semcancer.2017.04.015","article-title":"PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux.","volume":"4","author":"Mandala","year":"2018","journal-title":"Semin Cancer Biol"},{"key":"37","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.pharmthera.2013.12.004","article-title":"Molecular targets for cancer therapy in the PI3K\/AKT\/mTOR pathway.","volume":"14","author":"Janku","year":"2014","journal-title":"Pharmacol Ther"},{"key":"38","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1080\/15384047.2014.1002693","article-title":"PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition.","volume":"1","author":"Yu","year":"2015","journal-title":"Cancer Biol Ther"},{"key":"39","doi-asserted-by":"publisher","first-page":"109934","DOI":"10.1016\/j.cellsig.2021.109934","article-title":"mTOR modulates resistance to gemcitabine in lung cancer in an MTORC2 dependent mechanism.","volume":"8","author":"Dash","year":"2021","journal-title":"Cell Signal"},{"key":"40","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s13046-018-0947-4","article-title":"LAT2 regulates glutamine-dependent mTOR activation to promote glycolysis and chemoresistance in pancreatic cancer.","volume":"3","author":"Zhao","year":"2018","journal-title":"J Exp Clin Cancer Res"}],"container-title":["Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.204324","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T01:08:07Z","timestamp":1666228087000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.204324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,8]]},"references-count":40,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2022,10,15]]}},"alternative-id":["204324","36214762"],"URL":"https:\/\/doi.org\/10.18632\/aging.204324","relation":{},"ISSN":["1945-4589"],"issn-type":[{"value":"1945-4589","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,8]]}}}